Phase I safety and tolerability dose escalation study of microencapsulated hepatocyte intraperitoneal transplantation therapy in adult patients with liver failure: a study protocol.

ABSTRACT:

Introduction

China has a high prevalence of liver diseases, with about 300 million patients suffering from various types of liver diseases, where the incidence of severe liver diseases is 1%-3%. More than half a million people die from end-stage liver disease every year in China. In situ liver transplantation is the most effective treatment for liver failure, but only a limited number of patients undergo liver transplantation due to the shortage of donors. Hepatocyte transplantation requires only a certain number of hepatocytes rather than the whole liver, regardless of complex issues such as in vitro reconstruction of the three-dimensional structure of the liver, blood vessels and biliary ducts, enabling it to be safer and easier to promote in clinical practice than liver transpla

SUBMITTER: Yang T 

PROVIDER: S-EPMC12004478 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature